Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rare Complex Mutational Profile in an ALK Inhibitor-resistant Non-small Cell Lung Cancer.

Anticancer research - 1 May 2015

Azzato Elizabeth M, Deshpande Charuhas, Aikawa Vania, Aggarwal Charu, Alley Evan, Jacobs Benjamin, Morrissette Jennifer, Daber Robert

Abstract excerpt

Testing for somatic alterations, including anaplastic lymphoma receptor tyrosine kinase gene (ALK) rearrangements and epidermal growth factor receptor gene (EGFR) mutations, is standard practice in the diagnostic evaluation and therapeutic management of non-small cell lung cancer (NSCLC), where the results of such tests can predict response to targeted-therapy. ALK rearrangements, EGFR mutations and mutations in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to AMP-Activated Protein Kinase Kinases
Share to Anaplastic Lymphoma Kinase

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Crizotinib

Share to Gene Rearrangement

Share to Pyrazoles

Share to Pyridines

Share to ras Proteins

Share to Receptor Protein-Tyrosine Kinases

Source

Identifiers

PMID: 25964588

Genes

ALK
EGFR
KRAS
ATM
STK11

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rare Complex Mutational Profile in an ALK Inhibitor-resistant Non-small Cell Lung Cancer.PMID 25964588Read ↗

Novel therapeutic strategies for rare mutations in non-small cell lung cancer.Semantic proximity Read ↗

Overall signature of acquired KRAS gene changes in advanced non-small cell lung cancer patient with EGFR-TKI resistance.Semantic proximity Read ↗

KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' block.Semantic proximity Read ↗

Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2Semantic proximity Read ↗

ALK alterations and inhibition in lung cancer.Semantic proximity Read ↗

Rare mutations in non-small-cell lung cancer.Semantic proximity Read ↗

Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genesSemantic proximity Read ↗

Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma.Semantic proximity Read ↗

Treatment of Patients With Non-Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations.Semantic proximity Read ↗

An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.Semantic proximity Read ↗

Evaluation of the Mutation Profile via Next-Generation Sequencing in a Turkish Population With Non-small Cell Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.